MedTrace Logo

SAD Study to Assess the Safety, Tolerability, PK, and In-Vivo Performance of AMT-126 in Healthy Male and Female Subjects

NCT05476107 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-07-27

No results posted yet for this study

Summary

Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of AMT-126 and Optional Pharmacoscintigraphic Assessment of Oral AMT-126

Conditions

  • Healthy Volunteers

Interventions

DRUG

AMT-126

Single or daily dosing at doses A, B, C, D, E, F; G, H, and I

DRUG

Placebo

Single or daily dosing at doses A, B, C, D, E, F; G,H, and I

OTHER

Radioactive Tablet (Part 2 Only)

Single dose in two periods in Part 2 (optional)

Sponsors & Collaborators

  • Applied Molecular Transport

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-26
Primary Completion
2022-03-26
Completion
2022-03-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05476107 on ClinicalTrials.gov